Eiger BioPharmaceuticals announced that the U.S. FDA has accepted the Investigational New Drug application for lonafarnib in the treatment of both Hutchinson-Gilford Progeria Syndrome and progeroid laminopathies. Eiger is collaborating with The Progeria Research Foundation and plans to submit a new drug application to the FDA in 2019. There is no approved treatment for progeria or progeroid laminopathies. Lonafarnib is a first-in-class prenylation inhibitor in development for hepatitis delta virus infection and also progeria and progeroid laminopathies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.